Welcome to our dedicated page for Helius Med Technologies SEC filings (Ticker: HSDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage device makers like Helius Medical Technologies often bury pivotal updates—FDA feedback on PoNS, reimbursement milestones, cash-runway details—inside dense exhibits. Missing a single line about a new multiple-sclerosis study could upend your valuation. Stock Titan’s AI surfaces those details instantly, turning every line of the Helius Medical Technologies annual report 10-K simplified into clear, actionable data.
Need Helius Medical Technologies SEC filings explained simply? You’ll receive real-time alerts the moment a Helius Medical Technologies quarterly earnings report 10-Q filing or Helius Medical Technologies 8-K material events explained hits EDGAR. Understanding Helius Medical Technologies SEC documents with AI feels intuitive, not technical—section-by-section summaries spotlight device revenue, clinical-trial costs, and capital raises.
- Insider moves: Track Helius Medical Technologies Form 4 insider transactions real-time and pinpoint buying or selling before the market reacts.
- Executive pay: Drill into each Helius Medical Technologies proxy statement executive compensation without scrolling past pages of tables.
- Event catalysts: Rapidly assess 8-K disclosures on clinical results, supply agreements, or VA purchasing contracts.
From Helius Medical Technologies earnings report filing analysis to monitoring Helius Medical Technologies insider trading Form 4 transactions, coverage spans every form. Need a quick read on Helius Medical Technologies executive stock transactions Form 4? It’s already on your dashboard, complete with AI-powered commentary. Compare quarter-over-quarter PoNS unit sales, watch cash levels, and gauge regulatory momentum in minutes—all with Stock Titan’s real-time, AI-driven insight engine.
Helius Medical Technologies (Nasdaq: HSDT) filed an 8-K disclosing a 1-for-50 reverse stock split approved by shareholders and the board to regain compliance with Nasdaq’s minimum-bid requirement.
The split becomes effective at 5:00 p.m. ET on June 30 2025; trading will begin on a split-adjusted basis on July 1 2025. Outstanding shares will fall from roughly 33.8 million to 0.7 million, while authorized shares remain 150 million and par value stays $0.001.
- Fractional shares: rounded down for cash or rounded up to a whole share.
- Equity awards and warrants will be proportionally adjusted.
- New CUSIP: 42328V 876; transfer agent: Equiniti Trust.
The action, reported under Items 3.03 and 5.03, materially modifies holder rights and aims to avert a potential Nasdaq delisting.
Helius Medical Technologies, Inc. (Nasdaq: HSDT) filed a Form 8-K on June 23, 2025 to update investors on its Nasdaq listing status.
� Background: On March 31, 2025 Nasdaq Staff notified Helius that its stockholders� equity had fallen below the required US$2.5 million, triggering a potential delisting under Listing Rule 5550(b)(1). After a subsequent hearing, Nasdaq granted the Company an extension until June 30, 2025 to regain compliance.
� Capital raise: Helius completed a public offering on June 6, 2025, generating net proceeds of approximately US$8.1 million.
� Current status: The Company has furnished an unaudited interim consolidated balance sheet dated June 17, 2025 that gives effect to the offering. Management states that the pro-forma balance sheet shows stockholders� equity of at least US$2.5 million, which it believes restores compliance with the Nasdaq Stockholders� Equity Requirement.
� Next steps: Helius is awaiting formal confirmation from Nasdaq that all continued-listing criteria� including the equity threshold—have been satisfied.
No earnings figures, segment data, or other financial statements were provided beyond the balance-sheet reference.
Helius Medical Technologies (NASDAQ: HSDT) has reported a significant amendment to its 2022 Equity Incentive Plan following stockholder approval at a special meeting held on May 23, 2025. The amendment, initially adopted by the Board on April 22, 2025, has resulted in a substantial increase in the company's equity compensation pool.
Key developments:
- The Plan's share pool increased to 7.1 million shares on June 16, 2025
- The increase represents 20% of Fully Diluted Shares following the company's first registered offering after May 15, 2025
- The amendment was triggered by the completion of a Public Offering
This expansion of the equity incentive plan suggests Helius Medical Technologies is strengthening its ability to attract and retain talent through equity-based compensation. The significant increase in available shares indicates the company's commitment to aligning employee interests with shareholder value.
FAQ
What is the current stock price of Helius Med Technologies (HSDT)?
What is the market cap of Helius Med Technologies (HSDT)?
What is the core focus of Helius Medical Technologies Inc?
What conditions does the PoNS device target?
How does the PoNS device work?
What is the significance of neuroplasticity in Helius' treatment approach?
How does Helius generate revenue?
What makes Helius competitive in the neurotechnology space?
What role do research and clinical trials play for the company?
How is Helius engaging with regulatory bodies?
